跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ANTHRASIL - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ANTHRASIL
Authorized
STANDARD
ANTHRASIL
Emergent Biosolutions Canada Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6230a7c7b8fc95d0
Company
Emergent Biosolutions Canada Inc.
Type
Standard
Approval Details
Approval Id
6230a7c7b8fc95d0
Drug Approval Canada Name
ANTHRASIL
Product Name
ANTHRASIL
Status
Restricted Access
Status Date
2018-09-26
Din
02469588
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
80:04.00
Atc Original
J06BB19 ANTHRAX IMMUNOGLOBULIN
Atc Name
j 06 bb 19
Aig Number
0159650001
Company Name
Emergent Biosolutions Canada Inc.
Company Address
155 Innovation Drive, Winnipeg, Manitoba, Canada, R3T 5Y3
Company Detail Path
/organization/emergent-biosolutions-canada-inc
Company Information
Pharmaceutical Company Name
Emergent Biosolutions Canada Inc.
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
100 King St W
Active Ingredients
ANTHRAX IMMUNOGLOBULIN (HUMAN)
60 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6230a7c7b8fc95d0
Type
Standard
Back to Health Canada Approvals